Ying Tian

发表

Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression

Tongyu Lin, Chengcheng Guo, X. Pu, 2010, Journal of gastroenterology and hepatology.

Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study

Tongyu Lin, Chengcheng Guo, H. Hong, 2018, Leukemia & lymphoma.

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Hartmann, A. Zaniboni, T. Price, 2010 .

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen

Ying Huang, Tongyu Lin, Chengcheng Guo, 2020, Frontiers in Oncology.

A novel prognostic nomogram for patients with extragastric mucosa‐associated lymphoid tissue lymphoma: A multicenter study

Tongyu Lin, H. Hong, Hong-qiang Guo, 2022, Cancer medicine.

Non-Hodgkin's Lymphoma Involving the Ileocecal Region: A Single-institution Analysis of 46 Cases in a Chinese Population

Tongyu Lin, Ying Tian, Yuanyuan Zhao, 2012, Journal of clinical gastroenterology.

EGFR inhibitors sensitize non–small cell lung cancer cells to TRAIL-induced apoptosis

Y. Huang, Tongyu Lin, Ying Tian, 2011, Chinese journal of cancer.

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

Q. Cai, Tongyu Lin, Zhiming Li, 2021, Cancer biology & medicine.

Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study

Tongyu Lin, H. Hong, Ying Tian, 2018, Leukemia & lymphoma.

A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin’s lymphoma patients

Tongyu Lin, H. Hong, Ying Tian, 2020, Leukemia & lymphoma.

Platelet-derived alpha-granules are associated with inflammation in patients with NK/T-cell lymphoma-associated hemophagocytic syndrome.

Tongyu Lin, Chengcheng Guo, Ying Tian, 2019, Cytokine.

13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and Activating Caspase-3

Q. Cai, Tianxin Lin, Tongyu Lin, 2013, PloS one.

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

J. Hecht, S. Dakhil, W. Go, 2013 .

A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy

Tongyu Lin, H. Hong, Ying Tian, 2020, Cancer management and research.

Surgical resection followed by chemotherapy may be an effective treatment strategy for primary gastrointestinal natural killer/T-cell lymphoma: a single center experience

Tongyu Lin, Chengcheng Guo, H. Hong, 2014, Leukemia & lymphoma.

Chinese Anti鄄 Cancer a Ssociation

Yan Huang, Tongyu Lin, Chengcheng Guo, 2022 .

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Y. Humblet, S. Patterson, M. Peeters, 2013 .

Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Ying Huang, Z. Pan, Shaodan Zhang, 2013, Oncology letters.

Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue type

Qiulian Wu, Ying Tian, Yuanyuan Zhao, 2011, Tumor Biology.

A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment

H. Hong, Ying Tian, Zhao Wang, 2020, Annals of Hematology.

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs

Yan Huang, Zhiming Li, Ying Tian, 2012, Investigational New Drugs.

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.

J. Hecht, S. Dakhil, W. Go, 2015, Clinical colorectal cancer.

[Role of bone marrow-derived mesenchymal stem cells in reduction of graft-versus-host disease by effecting CD4+CD25+ regulatory T cells in rats].

Yan Li, Ying Tian, Yi-jun Huang, 2006, Zhongguo shi yan xue ye xue za zhi.

Prognostic Value of the Modified Systemic Inﬂammation Score in Patients With Extranodal Natural Killer/T-Cell Lymphoma

Chengcheng Guo, H. Hong, Ying Tian, 2020, Frontiers in Pharmacology.

Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine.

Chengcheng Guo, H. Hong, Ying Tian, 2013 .

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012 .

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

J. Tabernero, J. Jassem, J. Canon, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report

Ying Tian, Yating Zheng, Mengli Huang, 2023, Frontiers in oncology.